STXS Stereotaxis

Stereotaxis Reports 2025 Second Quarter Financial Results

Stereotaxis Reports 2025 Second Quarter Financial Results

ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025.

“We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption,” said David Fischel, Chairman and CEO. “This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy.”

“Recent FDA clearance of MAGiC Sweep was a significant milestone as Stereotaxis’ first FDA clearance for an interventional catheter in nearly 20 years. Initial sales of MAGiC Sweep this quarter will contribute, along with MAGiC and Map-iT, to ramping recurring revenue. We are proud of our recent regulatory successes and continue to expect multiple additional regulatory approvals in the coming weeks and months, in line with previously shared timelines. As we reach key regulatory milestones we are beginning to demonstrate the initial commercial impact of these innovations in supporting revenue growth, improved margins, and earnings accretion.”

“Our progress in establishing a new foundational product ecosystem is transformational clinically, commercially and strategically. Our recently completed equity financing offers us a strengthened balance sheet with which to accelerate adoption of our comprehensive innovation strategy as we reach key milestones. This is a critical year in which we are establishing the healthy foundations for a preeminent high-growth robotic surgery company.”

2025 Second Quarter Financial Results

Revenue for the second quarter of 2025 totaled $8.8 million, a 95% increase compared to $4.5 million in the prior year second quarter and a 18% increase sequentially compared to $7.5 million in the first quarter of 2025. System revenue for the second quarter was $3.0 million, compared to $0.2 million in the prior year second quarter, reflecting partial revenue recognition on two capital systems, including the first commercial GenesisX system. Recurring revenue was $5.8 million, growing 35% compared to $4.3 million in the prior year second quarter, reflecting contributions from Map-iT catheter revenue and the initial launch of MAGiC, Stereotaxis’ proprietary robotically navigated ablation catheter.

Gross margin for the second quarter was 52% of revenue. Recurring revenue gross margin was 68% and system gross margin was 22%. Gross margins remain impacted by acquisition-related accounting that temporarily reduces disposable margin and by fixed overhead allocated over low system production levels.

Operating expenses in the second quarter of $8.6 million include $2.6 million of non-cash charges for stock compensation expense, acquisition related contingent earnout consideration and amortization of acquired intangible assets. Decreased operating expenses include a favorable adjustment on acquisition related contingent earnout consideration. Excluding these non-cash charges, adjusted operating expenses in the quarter were $6.0 million, compared to $6.8 million for adjusted operating expenses in the prior year second quarter. The Company received a $0.5 million Employee Retention Tax Credit reducing current period operating expenses.

Operating loss and net loss in the second quarter of 2025 were ($4.0) million and ($3.8) million, respectively, compared to ($6.0) million and ($5.8) million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash charges, were ($1.4) million and ($1.3) million, respectively, compared to ($3.5) million and ($3.3) million in the previous year. Negative free cash flow for the second quarter was ($3.7) million, compared to ($3.1) million in the previous year.

Cash Balance and Liquidity

At June 30, 2025, Stereotaxis had cash and cash equivalents of $7.0 million and no debt. In July, Stereotaxis announced raising $12.5 million in a registered direct financing from a strategic industry partner and institutional investors, with a first closing of $8.5 million completed in July. Incorporating the net proceeds from this offering, Stereotaxis’ proforma cash balance would be $18.8 million in cash and no debt.

Forward Looking Expectations

Stereotaxis reiterates its expectation of double-digit revenue growth for the full year 2025, with system revenue of $2-3 million per quarter and recurring revenue scaling throughout the year to $7 million in the fourth quarter. These revenue expectations assume only modest contributions from GenesisX in Europe and no system revenue from China. Anticipated regulatory milestones and initial commercial launches in 2025 support substantial growth in 2026. Stereotaxis expects its balance sheet to allow it to advance its transformative product ecosystem to market, fund its commercialization, and profitably grow.

Conference Call and Webcast

Stereotaxis will host a conference call and webcast today, August 7, 2025, at 4:30 p.m. Eastern Time. To access the conference call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (International) and give the participant pass code 1064613. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at

About Stereotaxis

Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions, including tariffs, on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Company Contacts:

David L. Fischel

Chairman and Chief Executive Officer

Kimberly R. Peery

Chief Financial Officer

314-678-6100

 
STEREOTAXIS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
        
(in thousands, except share and per share amounts)Three Months Ended

June 30,
 Six Months Ended

June 30,
 2025 2024 2025 2024
        
Revenue:       
Systems$3,038  $240  $5,002  $2,852 
Disposables, service and accessories 5,760   4,262   11,268   8,530 
Total revenue 8,798   4,502   16,270   11,382 
        
Cost of revenue:       
Systems 2,366   187   4,033   2,087 
Disposables, service and accessories 1,853   1,002   3,594   2,016 
Total cost of revenue 4,219   1,189   7,627   4,103 
        
Gross margin 4,579   3,313   8,643   7,279 
        
Operating expenses:       
Research and development 1,777   2,273   4,127   4,516 
Sales and marketing 3,269   3,301   6,417   6,304 
General and administrative 4,002   3,760   8,497   7,226 
Other (492)  -   (492)  - 
Total operating expenses 8,556   9,334   18,549   18,046 
Operating loss (3,977)  (6,021)  (9,906)  (10,767)
        
Other expense (1)  (3)  (1)  (3)
Interest income, net 152   191   258   430 
Net loss$(3,826) $(5,833) $(9,649) $(10,340)
Cumulative dividend on convertible preferred stock (318)  (325)  (632)  (656)
Net loss attributable to common stockholders$(4,144) $(6,158) $(10,281) $(10,996)
        
Net loss per share attributed to common stockholders:       
Basic$(0.05) $(0.07) $(0.12) $(0.13)
        
Diluted$(0.05) $(0.07) $(0.12) $(0.13)
        
Weighted average number of common shares and equivalents:       
Basic 87,952,086   84,570,738   87,861,231   84,025,335 
        
Diluted 87,952,086   84,570,738   87,861,231   84,025,335 
                



 
STEREOTAXIS, INC.
CONSOLIDATED BALANCE SHEETS
 
 
(in thousands, except share amounts)June 30,

2025
 December 31,

2024
 (Unaudited)  
Assets   
Current assets:   
Cash and cash equivalents$6,967  $12,217 
Restricted cash - current -   219 
Accounts receivable, net of allowance of $582 at 2025 and 2024, respectively 4,393   3,824 
Inventories, net 9,608   8,331 
Prepaid expenses and other current assets 936   1,848 
Total current assets 21,904   26,439 
Property and equipment, net 3,284   3,573 
Goodwill 3,764   3,764 
Intangible assets, net 6,899   7,358 
Operating lease right-of-use assets 5,204   5,483 
Prepaid and other non-current assets 118   107 
Total assets$41,173  $46,724 
    
Liabilities and stockholders' equity   
Current liabilities:   
Accounts payable$6,730  $5,668 
Accrued liabilities 1,731   2,922 
Deferred revenue 5,843   6,804 
Current contingent consideration 5,839   5,638 
Current portion of operating lease liabilities 605   570 
Total current liabilities 20,748   21,602 
Long-term deferred revenue 1,057   2,064 
Long-term contingent consideration 6,384   6,126 
Operating lease liabilities 5,122   5,436 
Other liabilities 1,110   64 
Total liabilities 34,421   35,292 
    
Series A - Convertible preferred stock:   
Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 21,233 and 21,458 shares outstanding at 2025 and 2024, respectively 5,296   5,352 
Stockholders' equity:   
Common stock, par value $0.001; 300,000,000 shares authorized, 86,004,864 and 85,326,557 shares issued at 2025 and 2024, respectively 86   85 
Additional paid-in capital 572,950   567,926 
Treasury stock, 4,015 shares at 2025 and 2024 (206)  (206)
Accumulated deficit (571,374)  (561,725)
Total stockholders' equity 1,456   6,080 
Total liabilities and stockholders' equity$41,173  $46,724 
    


EN
07/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE

Stereotaxis Reports 2025 Second Quarter Financial Results

Stereotaxis Reports 2025 Second Quarter Financial Results ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. “We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption,” said David Fischel, Chairman and CEO. “This is an exciting milestone rich year with bro...

 PRESS RELEASE

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world’s first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia pat...

 PRESS RELEASE

Stereotaxis to Report Second Quarter 2025 Financial Results on August ...

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025 ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis second quarter 2025 financial results conferenc...

 PRESS RELEASE

Stereotaxis Announces $12.5 Million Registered Direct Offering of Comm...

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock Led by Strategic Industry Partner and Select Institutional InvestorsProceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, at...

 PRESS RELEASE

First Clinical Results from MAGiC Catheter Study Published in the Jour...

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is the first peer-reviewed literature s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch